XML 28 R8.htm IDEA: XBRL DOCUMENT v3.26.1
Consolidated Statements Of Cash Flows - USD ($)
 12 Months Ended
Jan. 25, 2026
Jan. 26, 2025
Jan. 28, 2024
Cash flows from operating activities:      
Net loss $ (40,376,000) $ (161,896,000) $ (1,092,029,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Depreciation and amortization 40,807,000 43,499,000 77,968,000
Amortization of right-of-use assets 5,522,000 5,872,000 6,484,000
Right-of-use asset impairment 0 0 3,884,000
Investment impairments and credit loss reserves, net 10,387,000 1,109,000 3,929,000
Impairment of goodwill 84,785,000 7,490,000 755,621,000
Intangible impairment 1,777,000 0 131,385,000
Accretion of deferred financing costs and debt discount 4,788,000 8,274,000 7,320,000
Write-off of deferred financing cost and debt discount 2,388,000 13,246,000 4,446,000
Loss on extinguishment of debt 0 143,467,000 0
Induced conversion expense 21,188,000 0 0
Interest rate swap termination (1,145,000) (3,579,000) 0
Deferred income taxes 7,874,000 (21,672,000) 40,636,000
Share-based compensation 57,723,000 68,036,000 40,170,000
Loss (gain) on disposition of business operations and assets 75,000 262,000 8,000
Equity in net (gains) losses of equity method investments (636,000) 547,000 (45,000)
Gain from sale of investments 0 (277,000) 0
Corporate owned life insurance, net 2,917,000 3,411,000 4,746,000
Amortization of inventory step-up 0 0 3,314,000
Changes in assets and liabilities:      
Accounts receivable, net 3,343,000 (28,348,000) 27,443,000
Inventories (30,652,000) (18,666,000) 57,308,000
Other assets (12,033,000) 3,137,000 1,817,000
Accounts payable 22,530,000 14,682,000 (44,346,000)
Accrued liabilities 5,011,000 (4,623,000) (118,517,000)
Other liabilities (5,105,000) (15,984,000) (5,462,000)
Net cash provided by (used in) operating activities 181,168,000 57,987,000 (93,920,000)
Cash flows from investing activities:      
Proceeds from sales of property, plant and equipment 8,000 97,000 410,000
Purchase of property, plant and equipment (9,783,000) (7,861,000) (29,185,000)
Proceeds from sale of investments 1,936,000 2,650,000 0
Purchase of investments 0 (434,000) (930,000)
Purchase of intangibles (6,022,000) (6,341,000) (1,915,000)
Acquisition, net of cash acquired (21,472,000) 0 0
Proceeds from corporate-owned life insurance 0 4,802,000 8,923,000
Premiums paid for corporate-owned life insurance (3,428,000) (4,800,000) 0
Net cash used in investing activities (38,761,000) (11,887,000) (22,697,000)
Cash flows from financing activities:      
Proceeds from revolving line of credit 0 68,250,000 70,000,000
Payments of revolving line of credit 0 (283,250,000) (5,000,000)
Payments of term loans (181,212,000) (441,413,000) (272,375,000)
Proceeds from convertible senior notes 402,500,000 0 250,000,000
Payments of convertible senior notes (280,950,000) 0 0
Repurchase of warrants (217,761,000) 0 0
Proceeds from unwind of convertible note hedge 242,251,000 0 0
Purchase of capped calls (31,395,000) 0 0
Proceeds from issuance of common stock, net of issuance costs 0 640,675,000 0
Proceeds from interest rate swap termination 295,000 4,776,000 0
Deferred financing costs (11,653,000) (824,000) (25,361,000)
Payments for employee share-based compensation payroll taxes (27,293,000) (14,025,000) (6,714,000)
Proceeds from exercise of stock options 4,150,000 4,335,000 0
Distributions to noncontrolling interest 0 (184,000) 0
Net cash (used in) provided by financing activities (101,068,000) (21,660,000) 10,550,000
Effect of foreign exchange rate changes on cash and cash equivalents 2,097,000 (1,282,000) (858,000)
Net increase (decrease) in cash and cash equivalents 43,436,000 23,158,000 (106,925,000)
Cash and cash equivalents at beginning of period 151,743,000 128,585,000 235,510,000
Cash and cash equivalents at end of period 195,179,000 151,743,000 128,585,000
Supplemental disclosure of cash flow information      
Interest paid 16,306,000 72,454,000 83,583,000
Income taxes paid 4,076,000 7,979,000 19,758,000
Non-cash items      
Capital expenditures in accounts payable 2,415,000 183,000 860,000
Accrued deferred financing costs 0 0 828,000
Accrued purchase of intangibles 2,157,000 1,600,000 0
Debt extinguished in exchange for common stock 0 188,050,000 0
Conversion of note into equity 0 0 1,271,000
Write-off of deferred financing costs pursuant to induced conversion $ 4,598,000 $ 0 $ 0